DE69430839D1 - Trizyklische Indol-2-carbonsäure Derivate als selektive NMDA Rezeptor Antagonisten - Google Patents

Trizyklische Indol-2-carbonsäure Derivate als selektive NMDA Rezeptor Antagonisten

Info

Publication number
DE69430839D1
DE69430839D1 DE69430839T DE69430839T DE69430839D1 DE 69430839 D1 DE69430839 D1 DE 69430839D1 DE 69430839 T DE69430839 T DE 69430839T DE 69430839 T DE69430839 T DE 69430839T DE 69430839 D1 DE69430839 D1 DE 69430839D1
Authority
DE
Germany
Prior art keywords
carboxylic acid
nmda receptor
acid derivatives
receptor antagonists
tricyclic indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430839T
Other languages
English (en)
Other versions
DE69430839T2 (de
Inventor
Ryu Nagata
Norihiko Tanno
Nobuyuki Ae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of DE69430839D1 publication Critical patent/DE69430839D1/de
Publication of DE69430839T2 publication Critical patent/DE69430839T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
DE69430839T 1993-11-17 1994-11-14 Trizyklische Indol-2-carbonsäure Derivate als selektive NMDA Rezeptor Antagonisten Expired - Fee Related DE69430839T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31274293 1993-11-17

Publications (2)

Publication Number Publication Date
DE69430839D1 true DE69430839D1 (de) 2002-07-25
DE69430839T2 DE69430839T2 (de) 2003-02-13

Family

ID=18032877

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430839T Expired - Fee Related DE69430839T2 (de) 1993-11-17 1994-11-14 Trizyklische Indol-2-carbonsäure Derivate als selektive NMDA Rezeptor Antagonisten

Country Status (7)

Country Link
US (1) US5496843A (de)
EP (1) EP0657427B1 (de)
CN (1) CN1061034C (de)
AT (1) ATE219486T1 (de)
CA (1) CA2135811A1 (de)
DE (1) DE69430839T2 (de)
TW (1) TW280819B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
EP0807631B1 (de) * 1996-05-15 2003-03-12 Sankyo Company Limited Tricyclische Verbindungen mit fungizider Wirkung, ihre Herstellung und ihre Verwendung
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
EP1163220A1 (de) * 1999-03-23 2001-12-19 Sumitomo Pharmaceuticals Company, Limited Tricyclische indol-2-carbonsäure verbindung als nmda rezeptor-antagonist
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
KR0178469B1 (ko) * 1990-07-16 1999-03-20 메이나드 알. 존슨 흥분성 아미노산 길항제
CA2054339C (en) * 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な３環性キノキサリンジオン誘導体
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
DE4242675A1 (de) * 1992-12-17 1994-06-23 Basf Ag Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
ATE219486T1 (de) 2002-07-15
US5496843A (en) 1996-03-05
EP0657427A1 (de) 1995-06-14
DE69430839T2 (de) 2003-02-13
CN1061034C (zh) 2001-01-24
CA2135811A1 (en) 1995-05-18
TW280819B (de) 1996-07-11
CN1107838A (zh) 1995-09-06
EP0657427B1 (de) 2002-06-19

Similar Documents

Publication Publication Date Title
EP0902007A4 (de) Chalcon-derivate und medikamente die diese enthalten
DK0870768T3 (da) Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler
ATE232520T1 (de) Imidazolidin-4-on derivate verwendbar als antikrebsmittel
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
PT867436E (pt) Derivados de n-aril-piperidina e sua utilizacao como ligandos do receptor 5-ht1b
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
DE69430839D1 (de) Trizyklische Indol-2-carbonsäure Derivate als selektive NMDA Rezeptor Antagonisten
EP0371805A3 (de) Piperidin-Derivate und diese enthaltende Hypotensiva
NO20000737D0 (no) Tetrahydro <gamma>-karboliner
ATE185806T1 (de) Oxopyridylchinoxalin derivate
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
ATE204278T1 (de) Serotoninergische ergolin derivate
DE69423055D1 (de) Indol Derivate als Glutamat Antagonisten
DK189389D0 (da) Heterotetracycliske lactamderivater
ES2149180T3 (es) Derivado de pirazolotiazolopirimidina.
EP0450232A3 (en) P-guanidino benzoic acid derivatives for treatment of cerebrovascular contraction

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee